DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Thyrocare Technologies Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 1 hr ago·6 Oct 2026, 1:30 pm

Thyrocare Tech

Thyrocare Technologies Limited has submitted a compliance certificate to the stock exchanges. This document confirms that the company has fulfilled all its obligations under SEBI's (Depositories and Participants) Regulations, 2018, specifically for the quarter ending September 30, 2026. This is a routine regulatory filing that serves as proof of the company's adherence to corporate governance and listing norms.

For investors, this news is largely procedural and carries no immediate financial implications. The filing indicates that Thyrocare is in good standing with market regulators, which is a standard requirement for maintaining a listing on Indian stock exchanges. It confirms that the company's depository-related processes are being followed correctly.

Investors should monitor the company's upcoming quarterly earnings reports to gauge its operational performance. While this regulatory update is neutral, it reinforces the company's compliance posture. The focus for the stock will likely remain on its core diagnostic services business and growth trajectory rather than this specific administrative filing.